CD19/22 Bi-specific CAR-T Cell Therapy
ConditionB Cell Malignancies
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age6-75
SponsorShenzhen Geno-Immune Medical Institute
About this trial
The purpose of this study is to assess the feasibility, safety and efficacy of anti-CD19/22 bi-specific CAR-T cell therapy in patients with CD19 and/or CD22 positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19/22 bi-specific CAR-T cells and their persistency in patients.
Eligibility criteria
Qualifiers
age older than 6 months.
malignant B cell surface expression of CD19 or CD22 molecules.
the KPS score over 80 points, and survival time is more than 1 month.
greater than Hgb 80 g/L.5. no contraindications to blood cell collection.
Disqualifiers
accompanied with other active diseases and difficult to assess patient response.
bacterial, fungal, or viral infection, unable to control.
living with HIV.4. active HBV or HCV infection.
Trial design
Treatments tested in this trial
- bi-4SCAR CD19/22 T cells
Treatment groups
60 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov